Investors Urged to Connect with Levi & Korsinsky for ESSA Pharma Inc. Legal Recourse

Levi & Korsinsky LLP has issued an important notice to investors of ESSA Pharma Inc. (NASDAQ: EPIX), encouraging them to take action regarding potential rights related to a class action lawsuit by March 25, 2025. This legal move addresses serious allegations of securities fraud that may impact many stakeholders involved with the company.

Class Action Overview

The class action lawsuit filed against ESSA Pharma Inc. centers around claims that the company made misleading statements and concealed crucial information that resulted in significant financial losses for investors. This lawsuit concerns transactions that occurred between December 12, 2023, and October 31, 2024. Thus, investors affected during this period should pay close attention to the developments.

The allegations specifically state that statements were made that misrepresented the efficacy of masofaniten when used in conjunction with enzalutamide. Plaintiffs argue that the combined treatment did not provide a clear benefit compared to using enzalutamide alone, contrary to what the company had asserted.

Additionally, it has been claimed that the M-E Combination Study, designed to evaluate the effectiveness of this treatment approach, was unlikely to meet its primary endpoints. This has raised concerns regarding the company’s marketing and development strategy, leading to speculation about the overstated prospects of masofaniten.

Importance of Action

In light of these developments, investors are encouraged to contact Levi & Korsinsky for guidance on how to proceed. The firm is well-known for its extensive experience in securities litigation and has previously secured hundreds of millions of dollars for aggrieved shareholders. They provide potential class members an opportunity to participate in the lawsuit without incurring out-of-pocket costs.

This is a crucial opportunity for investors to assert their rights and seek a possible recovery for their losses stemming from the alleged fraud. To ensure your voice is recognized, you must act prior to the deadline of March 25, 2025, when you can request the court to appoint you as lead plaintiff. However, it should be noted that you do not need to serve as a lead plaintiff to participate in any possible recovery.

Contact Information

Those interested in learning more about the lawsuit or filing their claims are encouraged to reach out directly to Joseph E. Levi, Esq., who can be contacted via email or phone. With over 70 dedicated professionals at Levi & Korsinsky committed to investor protection, you can ensure that your rights are well represented.

Levi & Korsinsky Contact Information:
Joseph E. Levi, Esq.
Email: [email protected]
Phone: (212) 363-7500

This legal notice serves as an essential reminder for investors to evaluate their potential claims carefully. The actions taken within the specified time frame could significantly influence their investment recovery options. Investors should not hesitate to seek legal advice and affirm their positions as necessary for the anticipated class action proceedings related to ESSA Pharma Inc.